Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate

Circulation

Volumn 95, Issue 1, 1997, Pages 118-124

  Cosmi, Benilde ^b   Fredenburgh, James C ^b   Rischke, Janice ^b   Hirsh, Jack ^b   Young, Edward ^b   Weitz, Jeffrey I ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b NONE

Author keywords

anticoagulants; heparin; plasma; proteins

Indexed keywords

DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031027986     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.1.118     Document Type: Article

References (14)

1. Hirsh J, van Aken WG, Callus AS, Dollery CT, Cade JF, Yung WJ. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
2. Hirsh J. Heparin. N Engl J Med. 1991:324:1565-1574.
3. Hull RD, Raskob GE, Hirsh J, Jay RM, LeClerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986:315:1109-1114.
4. Lindahl U, Backstrom G, Hook M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA. 1979;76:3198-3202.
5. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983;116:492-499.
6. Hook M, Bjork I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: separation of high-activity and low-activity species by affinity chromatography on immobilized antithrombin. FEBS Lett. 1976; 66:90-93.
7. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 1976; 69:570-577.
8. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem. 1986:261:3980-3986.
9. Rucinski B, Niewiaroski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb Haemost. 1990; 63:493-498.
10. Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein: mechanism and role in the neutralization of heparin in plasma. J Biol Chem. 1983;258: 3803-3808.
11. Preissner KT, Muller-Berghaus G. Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem. 1987;262:12247-12253.
12. Zammit A, Pepper DS, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb Haemost. 1993;70:951-958.
13. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins: an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639-643.
14. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992; 79:1-17.